Evidence map›Paper›PMID 40261568›Full record

ArticleDigestive diseases and sciences2025

Integrated Analysis of PSMB8 Expression and Its Potential Roles in Hepatocellular Carcinoma.

Ruijiao Lu, Xieyidai Abuduhailili, Yuxia Li, Senyu Wang, Xigang Xia, Yangchun Feng

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ruijiao LuDepartment of Medical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Xieyidai AbuduhaililiDepartment of Medical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Yuxia LiDepartment of Medical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Senyu WangGood Clinical Research Practice, The First Huizhou Affiliated Hospital of Guangdong Medical University, Guangdong, China.
Xigang XiaDepartment of Hepatobiliary Pancreatic Surgery, The First Huizhou Affiliated Hospital of Guangdong Medical University, Guangdong, China.
Yangchun FengDepartment of Medical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China. paopao1987123@163.comm.

Funding

Xinjiang Uygur Autonomous Region Tianchi Talent-Young Doctor 2023TCYCFYC
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) represents a highly aggressive malignancy with significant global health implications. The proteasome subunit beta type-8 (PSMB8) gene, known for its association with hepatitis B virus susceptibility, has emerged as a potential regulator of tumor progression. However, its functional role and clinical significance in HCC remain poorly characterized.

methodsWe conducted a comprehensive multi-omics analysis to elucidate the role of PSMB8 in HCC. PSMB8 expression profiles were derived from The Cancer Genome Atlas and validated using the GSE76427 dataset. Prognostic significance was assessed through Kaplan-Meier survival analysis. Then, we systematically evaluated the relationships between PSMB8 expression and clinicopathological features, somatic mutations, immune cell infiltration, immune regulatory genes, and immune checkpoint responses. Single-cell RNA sequencing data from the Tumor Immune Single-cell Hub database were analyzed to determine cell type-specific PSMB8 expression. Tissue-level validation was performed using multiplex immunofluorescence staining on HCC tissue microarrays.

resultsPSMB8 demonstrated significant overexpression in HCC tissues and exhibited strong prognostic value. Single-cell analysis revealed predominant PSMB8 expression in T and B cell populations. Notably, PSMB8 expression showed significant positive correlations with immune checkpoint molecules PD-L1/CD274 and CD27. Functional enrichment analysis implicated PSMB8 in multiple oncogenic pathways, particularly proteasome-related processes.

conclusionOur findings position PSMB8 as a promising prognostic biomarker and potential therapeutic target in HCC. The observed associations with immune checkpoint molecules and proteasomal pathways suggest its potential role in modulating tumor immunity and protein homeostasis, warranting further investigation into its mechanistic contributions to HCC progression.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsProteasome Endopeptidase ComplexBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisBiomarkers, TumorLMP7 proteinProteasome Endopeptidase ComplexHepatocellular carcinomaImmunofluorescencePrognosisPSMB8Tumor microenvironment

Identifiers

PMID40261568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.